I am pleased to report that the financial year 2017-18 has been a year of significantstrategic progress towards our pre-defined Our constant endeavours towards making SRL aresponsible corporate are reflected in the bedrock of our business strategies. We arefully committed to make a difference in the areas of Active Pharma Ingredients (API) andAdvance Pharma Intermediates by delivering niche solutions. Our constant engagement withour stakeholders allows to improve social environmental and economic performance of ouroperations.
Our financial performance during the year showed a satisfactory growth. Here are someof the key highlights: Revenues strengthened 6.57% from Rs. 4094 lakhs in 2016-17 to Rs.4363 lakhs in 2017-18 Operating profit strengthened 9.87% from Rs. 729 lakhs in 2016-17to Rs. 801 lakhs in 2017-18 PAT strengthened 55.57% from Rs. 330 lakhs in 2016-17 to Rs.513 lakhs in 2017-18
During the year we received all the necessary approvals for establishing ourmanufacturing facility to produce Pharma API and Intermediates at GIDC Dahej II District
Bharuch Gujarat. We are specifically focussing on developing molecules for the nicheoncological segment.growth with continued There are handful of players that derive suchproducts goals. and hence we stand a good opportunity to make our mark. We haveon-boarded a team of highly credible and experienced scientists that would be working onthe selected molecules. Besides our associate company Medicamen Biotech Limited willfurther provide us with the benefit of forward integration for our pharmaceutical valuechain. As we look forward we are focused on making the critical strategic choices thatare needed to drive lean disciplined operations and further strengthen our earningsfoundation all while leveraging our strategy to navigate fast-moving market dynamics.
I remain excited passionate and confident in this great company and its very brightfuture. Once again I thank you all the Stakeholders for your support as we build an evenstronger more profitable organisation going ahead.